Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Fibroblast growth factor homologous factors tune arrhythmogenic late NaV1.5 current in calmodulin binding–deficient channels
Jeffrey Abrams, Daniel Roybal, Nourdine Chakouri, Alexander N. Katchman, Richard Weinberg, Lin Yang, Bi-xing Chen, Sergey I. Zakharov, Jessica A. Hennessey, Uma Mahesh R. Avula, Johanna Diaz, Chaojian Wang, Elaine Y. Wan, Geoffrey S. Pitt, Manu Ben-Johny, Steven O. Marx
Jeffrey Abrams, Daniel Roybal, Nourdine Chakouri, Alexander N. Katchman, Richard Weinberg, Lin Yang, Bi-xing Chen, Sergey I. Zakharov, Jessica A. Hennessey, Uma Mahesh R. Avula, Johanna Diaz, Chaojian Wang, Elaine Y. Wan, Geoffrey S. Pitt, Manu Ben-Johny, Steven O. Marx
View: Text | PDF
Research Article Cardiology

Fibroblast growth factor homologous factors tune arrhythmogenic late NaV1.5 current in calmodulin binding–deficient channels

  • Text
  • PDF
Abstract

The Ca2+-binding protein calmodulin has emerged as a pivotal player in tuning Na+ channel function, although its impact in vivo remains to be resolved. Here, we identify the role of calmodulin and the NaV1.5 interactome in regulating late Na+ current in cardiomyocytes. We created transgenic mice with cardiac-specific expression of human NaV1.5 channels with alanine substitutions for the IQ motif (IQ/AA). The mutations rendered the channels incapable of binding calmodulin to the C-terminus. The IQ/AA transgenic mice exhibited normal ventricular repolarization without arrhythmias and an absence of increased late Na+ current. In comparison, transgenic mice expressing a lidocaine-resistant (F1759A) human NaV1.5 demonstrated increased late Na+ current and prolonged repolarization in cardiomyocytes, with spontaneous arrhythmias. To determine regulatory factors that prevent late Na+ current for the IQ/AA mutant channel, we considered fibroblast growth factor homologous factors (FHFs), which are within the NaV1.5 proteomic subdomain shown by proximity labeling in transgenic mice expressing NaV1.5 conjugated to ascorbate peroxidase. We found that FGF13 diminished late current of the IQ/AA but not F1759A mutant cardiomyocytes, suggesting that endogenous FHFs may serve to prevent late Na+ current in mouse cardiomyocytes. Leveraging endogenous mechanisms may furnish an alternative avenue for developing novel pharmacology that selectively blunts late Na+ current.

Authors

Jeffrey Abrams, Daniel Roybal, Nourdine Chakouri, Alexander N. Katchman, Richard Weinberg, Lin Yang, Bi-xing Chen, Sergey I. Zakharov, Jessica A. Hennessey, Uma Mahesh R. Avula, Johanna Diaz, Chaojian Wang, Elaine Y. Wan, Geoffrey S. Pitt, Manu Ben-Johny, Steven O. Marx

×

Figure 1

Cardiac-specific, FLAG-tagged TTX-sensitive NaV1.5-expressing transgenic mice.

Options: View larger image (or click on image) Download as PowerPoint
Cardiac-specific, FLAG-tagged TTX-sensitive NaV1.5-expressing transgenic...
(A) Diagram showing NaV1.5. The pore-forming α-subunit is a pseudotetramer of transmembrane domains (I–IV) linked by intracellular loops. The channel’s inactivation gate is in the III–IV linker. The best-established CaM binding site is on the C-terminal domain, where the FHF binding site also resides. (B) Schematic of binary transgene system. The expression of reverse tetracycline-controlled transactivator (rtTA) is driven by the cardiac-specific α-myosin heavy chain promoter. The cDNAs for FLAG-F1759A-NaV1.5 or FLAG-tagged TTX-sensitive NaV1.5 were ligated behind 7 tandem tetO sequences. (C) Anti-FLAG antibody immunoblots of cleared lysates of hearts from pWT, IQ/AA, and nontransgenic mice. Representative images of 3 independent experiments. (D) Immunostaining of nontransgenic, pWT, and IQ/AA mice cardiomyocytes. Nontransgenic cardiomyocytes: primary antibody, anti-NaV1.5 antibody. pWT and IQ/AA cardiomyocytes: primary antibody, anti-FLAG antibody. FITC-conjugated secondary antibody was used for all experiments. Scale bar: 5 μm. Representative of 20 cardiomyocytes from at least 3 independent cardiomyocyte isolations for all groups. (E–G) Exemplar whole cell Na+ current trace of ventricular cardiomyocyte from nontransgenic, pWT, and IQ/AA transgenic mice in the absence (black) and presence (red) of 20 nM TTX. Representative of n = 13, 21, and 44 cells, from left to right. Vertical scale bars: 10 pA/pF; horizontal scale bars: 5 ms. (H) Graph showing effect of 20 nM TTX on peak Na+ current. ****P < 0.0001 by paired t test. For nontransgenic, P = 0.61. n = 13, 21, and 44 cells from left to right. (I) Graph of fraction transgenic Na+ current for pWT and IQ/AA. Mean ± SEM. n = 21 and 44 cells from left to right. P = 0.73 by t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts